Dendreon to Host Conference Call on May 9 to Announce First Quarter Financial Results -- Company Announces Webcast Presentations at Upcoming Conferences -- Bank of America Merrill Lynch 2013 Health Care Conference Business Wire SEATTLE -- April 24, 2013 April 24, 2013--Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Thursday, May 9, 2013, at 9:00 a.m. EDT to review first quarter financial results. Access to the discussion may be obtained as follows: Time: 9:00 a.m. EDT / 6:00 a.m. PDT Date: May 9, 2013 Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international); conference pass code: 53497612 Webcast: www.dendreon.com (homepage and investor relations section) A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 53497612. The replay will be available from 12:00 p.m. EDT on Thursday, May 9, until 11:59 p.m. EDT on Monday, May 15. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com. Dendreon Corporation also announced that management will present at the following conferences: *Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas, NV, on May 14 at 1:40 p.m. PDT *Deutsche Bank Securities 38th Annual dbAccess Health Care Conference in Boston, MA, on May 30, 2012, at 10:40 a.m. EDT The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replays, go to the Investor Relations section of the website. About Dendreon Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE^® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/. Contact: Dendreon Corporation Corporate Communications Lindsay Rocco, 862-596-1304 firstname.lastname@example.org or Dendreon Corporation Investor Relations Nicole Soley, 206-455-2220 InvestorRelations@dendreon.com
Dendreon to Host Conference Call on May 9 to Announce First Quarter Financial Results
Press spacebar to pause and continue. Press esc to stop.